DOCK2 Promotes Asthma Development by Eliciting Airway Epithelial–Mesenchymal Transition
American Journal of Respiratory Cell and Molecular Biology · 01.09.2023 · 69 (3) · 310-320
DOI: 10.1165/rcmb.2022-0273oc ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Respiratory Cell and Molecular Biology, online erschienen am 01.09.2023. Verfasst von Ning Shi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Missouri School of Medicine, Columbia, Missouri. Hauptthemen laut MEDLINE: Transforming Growth Factor beta1, Asthma. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, BLRD VA, National Heart and Lung Institute.
Abstract (Originalsprache)
Epithelial–mesenchymal transition (EMT) contributes to airway remodeling, a predominant feature of asthma. DOCK2 (dedicator of cytokinesis 2) is an innate immune signaling molecule involved in vascular remodeling. However, it is unknown if DOCK2 plays a role in airway remodeling during asthma development. In this study, we found that DOCK2 is highly induced in both normal human bronchial epithelial cells treated with house dust mite (HDM) extract and human asthmatic airway epithelium. DOCK2 is also upregulated by TGF-β1 (transforming growth factor β1) during EMT of human bronchial epithelial cells. Importantly, knockdown of DOCK2 inhibits, and overexpression of DOCK2 promotes, TGF-β1–induced EMT. Consistently, DOCK2 deficiency suppresses the EMT of airway epithelium, attenuates the subepithelial fibrosis, and improves pulmonary function in HDM-induced asthmatic lungs. These data suggest that DOCK2 plays an important role in EMT and asthma development. Mechanistically, DOCK2 interacts with transcription factor FoxM1 (forkhead box M1), which enhances FoxM1 binding to mesenchymal marker gene promoters and further promotes mesenchymal marker gene transcription and expression, leading to EMT. Taken together, our study identifies DOCK2 as a novel regulator for airway EMT in an HDM-induced asthma model, thus providing a potential therapeutic target for treatment of asthma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, University of Missouri School of Medicine, Columbia, Missouri.
- Department of Neurological Intensive Care Unit, Taihe Hospital, Shiyan, China; and.
- The Research Service, Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri.
ORCID-Profile: Shi-You Chen
Förderung
- NHLBI NIH HHS
- BLRD VA
- National Heart and Lung Institute
Zitieren
APA
Shi, N., Zhang, J., & Chen, S. Y. (2023). DOCK2 Promotes Asthma Development by Eliciting Airway Epithelial–Mesenchymal Transition. American Journal of Respiratory Cell and Molecular Biology, 69(3), 310-320. https://doi.org/10.1165/rcmb.2022-0273oc
Vancouver
Shi N, Zhang J, Chen SY. DOCK2 Promotes Asthma Development by Eliciting Airway Epithelial–Mesenchymal Transition. American Journal of Respiratory Cell and Molecular Biology. 2023;69(3):310-320. doi:10.1165/rcmb.2022-0273oc
BibTeX
@article{Shi2023,
author = {Shi, Ning and Zhang, Jing and Chen, Shi-You},
title = {DOCK2 Promotes Asthma Development by Eliciting Airway Epithelial–Mesenchymal Transition},
journal = {American Journal of Respiratory Cell and Molecular Biology},
year = {2023},
volume = {69},
number = {3},
pages = {310--320},
doi = {10.1165/rcmb.2022-0273oc}
}
EUVIMED